New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis

(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news